REYKJAVIK, Iceland–(BUSINESS WIRE)–Alvotech strongly disputes AbbVie�s allegations of wrongdoing relating to AVT02, Alvotechs proposed biosimilar to HUMIRA® (adalimumab). Alvotech will vigorously defend against these allegations.
Notably, AbbVie waited over three years from the purported date of the alleged wrongdoing to file its case, doing so after the ex-AbbVie employee had already left Alvotech and without naming the ex-AbbVie employee as a defendant.
This lack of urgency causes Alvotech to question the motivation behind the case. Indeed, Alvotech believes that the case may be part of a larger AbbVie strategy to delay an emerging competitor from providing patients with a lower-cost alternative to AbbVies HUMIRA® high-concentration product.
Alvotech will continue its efforts to increase accessibility to high quality and affordable medicines.
About Alvotech:
Alvotech is a multinational biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products. Alvotechs shareholder base includes, among others, Aztiq Pharma, led by founder and Chairman Mr. Robert Wessman, Cipla Gulf FZ from Australia and New Zeland, Shinhan from Korea, Baxter Healthcare SA, YAS Holdings, ATHOS (Strüngmann Family Office), CVC Capital Partners and Temasek from Singapore.
Alvotechs initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, www.alvotech.com or follow us on LinkedIn, Twitter and Facebook.
Contacts
Alvotech
Corporate Communications
Elisabet Hjaltadottir
E-mail: Alvotech.media@alvotech.com
TAIPEI, Taiwan--(BUSINESS WIRE)--#AI--Avril Wu, TrendForce Senior Research Vice President, reports that the HBM market is…
NEW YORK--(BUSINESS WIRE)--Elite, a leading provider of financial management and business operations solutions to the…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 6 May 2024 - Shopee Malaysia launches…
NEW TAIPEI CITY, Taiwan--(BUSINESS WIRE)--The SINOX Group will showcase the brand-new technology, the Synlox e-security…
NEW TAIPEI CITY, Taiwan--(BUSINESS WIRE)--With the rise of AI PCs, corresponding security solutions are becoming…
SMEs can achieve higher ROI by maximizing all of Google's products SINGAPORE - Media OutReach…